Enanta Pharmaceuticals (NASDAQ:ENTA) PT Lowered to $54.00 at Royal Bank of Canada

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) had its price objective trimmed by Royal Bank of Canada from $65.00 to $54.00 in a report published on Tuesday morning, The Fly reports. The brokerage currently has a sector perform rating on the biotechnology company’s stock.

Several other equities research analysts have also recently issued reports on the company. Oppenheimer raised their price objective on Enanta Pharmaceuticals from $53.00 to $59.00 and gave the stock a market perform rating in a report on Wednesday, August 10th. StockNews.com started coverage on Enanta Pharmaceuticals in a report on Wednesday, October 12th. They issued a hold rating for the company. SVB Leerink increased their price objective on shares of Enanta Pharmaceuticals from $44.00 to $50.00 and gave the stock a market perform rating in a report on Monday, August 1st. Finally, JMP Securities boosted their target price on shares of Enanta Pharmaceuticals from $103.00 to $137.00 and gave the company a market outperform rating in a report on Tuesday, August 9th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Enanta Pharmaceuticals has a consensus rating of Hold and an average price target of $67.43.

Enanta Pharmaceuticals Trading Down 1.0 %

ENTA stock opened at $45.00 on Tuesday. The company’s 50-day moving average price is $47.82 and its 200 day moving average price is $51.17. Enanta Pharmaceuticals has a 52 week low of $37.59 and a 52 week high of $92.90. The company has a market cap of $932.85 million, a P/E ratio of -7.61 and a beta of 0.53.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last announced its quarterly earnings results on Monday, November 21st. The biotechnology company reported ($1.27) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.10. The business had revenue of $20.32 million for the quarter, compared to analyst estimates of $22.86 million. Enanta Pharmaceuticals had a negative return on equity of 34.73% and a negative net margin of 141.31%. The company’s quarterly revenue was down 13.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.22) EPS. On average, equities research analysts expect that Enanta Pharmaceuticals will post -2.99 earnings per share for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of large investors have recently modified their holdings of ENTA. BlackRock Inc. lifted its holdings in Enanta Pharmaceuticals by 2.9% in the 3rd quarter. BlackRock Inc. now owns 3,621,795 shares of the biotechnology company’s stock worth $187,864,000 after buying an additional 103,059 shares in the last quarter. State Street Corp raised its position in shares of Enanta Pharmaceuticals by 29.9% in the 2nd quarter. State Street Corp now owns 1,699,428 shares of the biotechnology company’s stock valued at $80,332,000 after purchasing an additional 390,842 shares in the last quarter. RA Capital Management L.P. purchased a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at approximately $68,633,000. Northern Trust Corp grew its position in shares of Enanta Pharmaceuticals by 0.3% during the second quarter. Northern Trust Corp now owns 931,291 shares of the biotechnology company’s stock worth $44,022,000 after buying an additional 3,198 shares in the last quarter. Finally, Fairmount Funds Management LLC raised its holdings in Enanta Pharmaceuticals by 21.1% in the first quarter. Fairmount Funds Management LLC now owns 469,264 shares of the biotechnology company’s stock valued at $33,402,000 after acquiring an additional 81,864 shares in the last quarter. Institutional investors and hedge funds own 97.09% of the company’s stock.

About Enanta Pharmaceuticals

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

See Also

The Fly logo

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.